InMed Pharmaceuticals raises ~$6M in private placement at $3.30/share, priced at premium to market

InMed Pharmaceuticals Inc.

Raised ~$6M gross via sale of 1,818,185 shares/pre-funded warrants at $3.30 per share.
Issued preferred investment options to buy up to 3,272,733 shares at $3.044/sh, expiring in 7 years.
Investors cancelled prior options for ~1.38M shares, partially offsetting dilution.
Placement agent H.C. Wainwright received options for 118,182 shares at $4.125/sh.
Proceeds to fund pipeline development, manufacturing, IP, and general working capital.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-11-17).

Action: entry
Agreement: equity purchase
Counterparty: the Purchasers
Effective: 2022-11-17

Exact text from the filing

In connection with the Private Placement, the Company entered into a Registration Rights Agreement with the Purchasers, dated November 17, 2022 (the “Registration Rights Agreement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2022-09-09).

Action: entry
Agreement: underwriting
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2022-09-09

Exact text from the filing

The Company entered into an engagement letter with Wainwright, dated September 9, 2022 (the “Engagement Letter”), pursuant to which Wainwright agreed to serve as the Company’s exclusive placement agent, advisor or underwriter in certain offerings, including the Private Placement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

InMed Pharmaceuticals Inc. entered into Purchase Agreement with two institutional accredited investors valued at approximately $6.0 million (effective 2022-11-17).

Action: entry
Agreement: equity purchase
Counterparty: two institutional accredited investors
Value: approximately $6.0 million
Effective: 2022-11-17

Exact text from the filing

On November 17, 2022, InMed Pharmaceuticals Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with two institutional accredited investors (the “Purchasers”), for the sale and issuance of an aggregate of 1,818,185 of its common shares (or pre-funded warrants in lieu thereof) at a purchase price of $3.30 per share (or pre-funded warrant in lieu thereof).

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-074323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.